
LFCR Stock Forecast & Price Target
LFCR Analyst Ratings
Bulls say
Lifecore Biomedical is experiencing impressive recent technology transfer wins which are expected to have a significant impact on their financials in the long term. The company's continued execution of its strategic vision, driven by CEO Paul Josephs and his team, has led to a broader business scope and potential for growth. With a 20x multiple applied to their adjusted EBITDA and accounting for potential risks, we have arrived at an OUTPERFORM rating and a 12-month price target of $6.50.
Bears say
Lifecore Biomedical is in the execution phase of its turnaround story led by CEO Paul Josephs, with significant progress being made in terms of new business wins and expense management. The recent hire of Amber Shook as Head of Business Transformation suggests a focus on becoming more efficient. However, the company's high level of leverage and low cash position may raise concerns about its ability to sustain growth and meet its longer-term targets.
This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.
LFCR Analyst Forecast & Price Prediction
Start investing in LFCR
Order type
Buy in
Order amount
Est. shares
0 shares